Dymon Asia Capital »

Protagonist Therapeutics shares owned by Dymon Asia Capital

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by Dymon Asia Capital from 13F filings

Historical chart of Dymon Asia Capital investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by Dymon Asia Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by Dymon Asia Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $873k 10k 87.34

More positions owned by Dymon Asia Capital

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Silver Tr Ishares Call Option (SLV)
NVIDIA Corporation (NVDA)
Ishares Tr Mbs Etf (MBB)
Meta Platforms Cl A Call Option (META)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Microsoft Corporation (MSFT)
Broadcom (AVGO)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Home Depot (HD)
Qualcomm (QCOM)
Synopsys Call Option (SNPS)
Spdr Gold Tr Gold Shs Call Option (GLD)
Alphabet Cap Stk Cl A (GOOGL)
Taiwan Semiconductor Mfg Sponsored Ads (TSM)

View all positions for Dymon Asia Capital

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Vanguard Group
Rtw Investments
State Street Corporation
UBS Group
BVF
Johnson & Johnson
Wellington Management Company
Invesco
Geode Capital Management
Woodline Partners
Driehaus Capital Management
Henderson Group
ADAR1 Capital Management

View all funds holding Protagonist Therapeutics